ChiaJEAngSPUsmanMHKrittanawongCMukherjeeD.Trends, characteristics and outcomes in breast cancer survivors with STEMI. Angiology. 2026;77:375-84.
2.
OkşulMŞenerYZSarıkayaY, et al. Breast artery calcification as an opportunistic predictor of cardiovascular disease. Ir J Med Sci. 2023;192:625-31.
3.
Abdel-QadirHBobrowskiDZhouL, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc. 2021;10:e018393.
4.
ShuggTNguyenTHuaX, et al. Factors associated with the recovery of left ventricular ejection fraction in patients with anthracycline-induced left ventricular dysfunction. J Cardiovasc Pharmacol Ther. 2025;30:10742484241304304.
5.
LabibDHaykowskyMSonnexE, et al. Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch). Cardiooncology. 2025;11:13.
6.
NeilanTGQuinagliaTOnoueT, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA. 2023;330:528-36.
7.
BonattoMGFerreiraSAvilaM, et al. Effects of sacubitril-valsartan on prevention of cardiotoxicity in high-risk patients undergoing anthracycline chemotherapy: a double-blind randomized placebo-controlled clinical trial – the SARAH trial. Circulation. 2024;150:e724-5.
8.
LyonARLópez-FernándezTCouchLS, et al. 2022ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229-361.
9.
MeattiniICuriglianoGTerzianiF, et al. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. Med Oncol. 2017;34:75.
10.
Khosrow-KhavarFFilionKBAl-QurashiS, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28:487-96.
11.
YuQXuYYuEZhengZ.Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: a systematic review and meta-analysis. J Clin Pharm Ther. 2022;47:575-87.
12.
RygielK.Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials. Indian J Pharmacol. 2016;48:490.
13.
YandrapalliSMalikAHPemmasaniG, et al. Risk factors and outcomes during a first acute myocardial infarction in breast cancer survivors compared with females without breast cancer. Am J Med. 2020;133:444-51.
14.
MadiasJE.Right versus left breast radiation and coronary artery disease: is there a differential?Acta Cardiol. 2023;78:5-12.
15.
CarlsonLEWattGPTonorezosES, et al. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncol. 2021;3:381-92.
16.
MiloMLHThorsenLBJJohnsenSP, et al. Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: a population-based Danish Breast Cancer Group study. Radiother Oncol. 2021;157:106-13.
